FrancophonIA/ELRC3.0 huggingface dataset:
English: 10.2 mm, round, normal convex, white film-coated tablets debossed “OZ” over “10” on one side and “G” on the other side.
Estonian: OLANSAPIIN MYLAN 10 mg õhukese polümeerikattega tabletid Ümarad valged normaalse kumerusega õhukese polümeerikattega 10,2 mm tabletid, mille ühel küljel on pimetrükk „OZ“ ja „10“ ning teisel küljel „G“.
English: Mutagenicity
Estonian: Mutageensus.
English: 23 May 2014
Estonian: 23. mai 2014
English: The applicant requested a re-examination of the opinion.
Estonian: Taotleja taotles arvamuse taasläbivaatamist.
English: What is Masiviera?
Estonian: Mis on Masiviera?
English: The company also presented various supporting analyses and information from a supportive study.
Estonian: Ettevõte esitas ka mitmesuguseid toetavaid analüüse ja toetava uuringu teavet.
English: In addition, Masiviera was associated with significant toxicity.
Estonian: Lisaks on Masivierat seostatud olulise toksilisusega.
English: In addition, some concerns about the quality of the medicine were not yet resolved.
Estonian: Peale selle olid lahendamata ravimi teatud kvaliteediprobleemid.
English: The main measure of effectiveness was how long the patients survived with their disease.
Estonian: Efektiivsuse põhinäitaja oli aeg, kui kaua patsiendid elasid haiguse süvenemiseta.
English: By blocking these receptors, Masiviera might help in controlling cell division and thereby slow down the growth of the cancer.
Estonian: Nende retseptorite blokeerimisega võib Masiviera aidata piirata rakkude jagunemist ja seega aeglustada vähi kasvamist.
English: Refusal of the marketing authorisation for Masiviera (masitinib)
Estonian: Masiviera (masitiniib) müügiloa andmisest keeldumine
English: Although the company presented analyses suggesting that there was a benefit in a subgroup of patients with certain genetic changes associated with more aggressive disease, and in a subgroup of patients with pain, the study was not designed to show benefit in these smaller groups, and the Committee considered that further study would be needed to demonstrate such a benefit.
Estonian: Kuigi ettevõte esitas analüüsid, mille järgi oli ravim kasulik patsientide alamrühmas, kellel olid agressiivsema haigusega seonduvad teatud geenimuutused, ja patsientide alamrühmas, kellel esines valu, ei olnud uuringu eesmärk tõendada ravimi kasulikkust nendes väikestes rühmades ning komitee leidis, et sellise kasulikkuse tõestamiseks on vaja teha lisauuring.
English: The company presented results of one main study involving 353 patients with advanced or metastatic pancreatic cancer.
Estonian: Ettevõte esitas andmed ühe põhiuuringu kohta, milles osales 353 kaugelearenenud või metastaatilise kõhunäärmevähiga patsienti.
English: If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.
Estonian: Kui osalete ravimi kliinilises uuringus või eriloaga kasutamise programmis ja vajate oma ravi kohta lisateavet, pöörduge ravi määranud arsti poole.
English: Refusal of the marketing authorisation for Masiviera (masitinib) EMA/327117/2014
Estonian: Masiviera (masitiniib) müügiloa andmisest keeldumine EMA/298222/2014
English: Masiviera was expected to be used to treat adults with cancer of the pancreas (an organ of the digestive system) that is locally advanced or metastatic (has spread to other parts of the body), nonresectable (unsuitable for surgery) and is accompanied by at least moderate pain.
Estonian: Masivierat kavatseti kasutada täiskasvanute raviks, kellel on kõhunäärme (teatud seedeelund) vähk, mis on lokaalselt kaugelearenenud või metastaatiline (levinud organismis ka mujale), eemaldamatu (seda ei saa opereerida) ja millega kaasneb vähemalt mõõdukas valu.
English: The company that applied for authorisation is AB Science.
Estonian: Müügiluba taotles AB Science.
English: Therefore, the CHMP concluded that the benefits of Masiviera did not outweigh its risks and maintained the previous recommendation that the medicine be refused marketing authorisation.
Estonian: Komitee järeldas seetõttu, et Masiviera kasulikkus ei ole suurem kui kaasnevad riskid, ja jättis kehtima eelmise soovituse ravimi müügiloa andmisest keelduda.
English: The Committee confirmed its opinion that the effectiveness of Masiviera had not been sufficiently demonstrated in pancreatic cancer.
Estonian: Komitee kinnitas oma arvamust, et Masiviera efektiivsus ei ole kõhunäärmevähi ravis piisavalt tõestatud.
English: On 23 January 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Masiviera, intended for the treatment of advanced inoperable pancreatic cancer.
Estonian: 23. jaanuaril 2014 võttis inimravimite komitee vastu negatiivse arvamuse, soovitades kaugelearenenud opereerimatu kõhunäärmevähi raviks kasutatava ravimi Masiviera müügiloa andmisest keelduda.
English: Furthermore, the CHMP had concerns about the quality of the product, in particular about the impurities to which patients might be exposed and about whether commercial batches of the medicine would have the same quality as those used for the studies.
Estonian: Inimravimite komitee leidis ka toote kvaliteedi probleeme, eelkõige seoses lisanditega, millega patsiendid võivad kokku puutuda, ja sellega, kas ravimi kaubanduslikud partiid on sama kvaliteediga kui uuringupartiid.
English: Masiviera was compared with placebo (a dummy treatment) as an addition to treatment with gemcitabine.
Estonian: Masivierat võrreldi platseeboga (näiv ravim) mõlema lisamisel gemtsitabiiniga toimuvale ravile.
English: These enzymes can be found in some receptors on the surface of cells, including the receptors that are involved in stimulating cancer cells to divide
Estonian: Neid ensüüme leidub vähiraku pinna teatud retseptorites, sealhulgas retseptorites, mis osalevad vähirakkude vohamise stimuleerimisel.
English: For more information, see here.
Estonian: Lisateave on siin.
English: How is Masiviera expected to work?
Estonian: Milline on Masiviera eeldatav toime?
English: It was to be available as tablets.
Estonian: Masivierat kavatseti turustada tablettidena.
English: At the time of the initial evaluation, the CHMP noted that the results of the main study with Masiviera did not show effectiveness in the overall group of patients with advanced or metastatic pancreatic cancer.
Estonian: Esmasel hindamisel märkis inimravimite komitee, et Masiviera põhiuuringu tulemused ei näidanud efektiivsust kaugelearenenud või metastaatilise kõhunäärmevähi patsientide kogurühmas.
English: During the re-examination the CHMP looked again at the data from the company, including a proposal for a conditional authorisation in a restricted group of patients, and also consulted a group of experts in the treatment of pancreatic cancer.
Estonian: Taasläbivaatamisel vaatas inimravimite komitee uuesti läbi ettevõtte esitatud andmed, sealhulgas piiratud patsiendirühmas kasutamise tingimusliku müügiloa taotluse, ja konsulteeris kõhunäärmevähi ravi spetsialistidega.
English: Masiviera is an anticancer medicine that contains the active substance masitinib.
Estonian: Masiviera on vähivastane ravim, mis sisaldab toimeainena masitiniibi.
English: The effects of Masiviera were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Masiviera toimet muude katsetega.
English: The company informed the CHMP that there were no consequences for patients in clinical trials or compassionate use programmes.
Estonian: Ettevõte teatas inimravimite komiteele, et kliinilistes uuringutes või eriloaga kasutamise programmides osalevatele patsientidele keeldumine mõju ei avalda.
English: It was to be used in combination with another cancer medicine, gemcitabine.
Estonian: Seda kavatseti kasutada koos gemtsitabiiniga (samuti vähiravim).
English: Masitinib was designated an ‘orphan medicine' (a medicine to be used in rare diseases) on 28 October 2009 for the treatment of pancreatic cancer.
Estonian: Masitiniib nimetati 28. oktoobril 2009 kõhunäärmevähi ravi harvikravimiks.
English: The active substance in Masiviera, masitinib, is a tyrosine-kinase inhibitor.
Estonian: Masiviera toimeaine masitiniib on türosiinkinaasiinhibiitor ehk aine, mis blokeerib ensüüme türosiinkinaase.
English: What was Masiviera expected to be used for?
Estonian: Milleks kavatseti Masivierat kasutada?
English: Strength
Estonian: Kangus
English: Invented name
Estonian: Nimi
English: Pharmaceutical Form Route of administration Packaging
Estonian: Pakendi iseloomustus Pakendi suurus
English: (Invented) name Strength Pharmaceutical form Route of administration
Estonian: Tugevus Ravimvorm
English: MA EU Number
Estonian: Müügiloa nr Euroopa Liidus
English: Further information on Rxulti can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Rxulti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Rxulti?
Estonian: Mis meetmed võetakse, et tagada Rxulti ohutu ja efektiivne kasutamine?
English: In patients taking certain other medicines the doctor may need to adjust the dose of Rxulti.
Estonian: Teatud teisi ravimeid võtvatel patsientidel võib arstile vajalik olla Rxulti annuse kohandamine.
English: Schizophrenia is a mental illness with symptoms such as delusions, disorganised thinking and speech, suspiciousness and hallucinations (seeing, hearing or feeling things that are not there).
Estonian: Skisofreenia on vaimuhaigus, mille sümptomite hulgas on meelepetted, mõttekäigu ja kõne häired, kahtlustamine ja hallutsinatsioonid (patsient näeb või kuuleb asju, mida pole olemas).
English: Based on available data, it is not possible to say how Rxulti compares with other medicines of the same type.
Estonian: Olemasolevate andmete põhjal ei ole võimalik öelda, milline on Rxulti toime võrreldes teiste sama tüüpi ravimitega.
English: The Agency decided that Rxulti's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Rxulti kasulikkus on suurem kui sellega kaasnevad riskid, ja lubati ravimi kasutamine ELis.
English: Rxulti (brexpiprazole)
Estonian: Rxulti (brekspiprasool)
English: Rxulti is available as tablets (0.25, 0.5, 1, 2, 3 and 4 mg) to be taken by mouth.
Estonian: Rxulti turustatakse suukaudsete tablettidena (0,25; 0,5; 1; 2; 3 ja 4 mg).
English: The safety profile of Rxulti is similar to other antipsychotic medicines.
Estonian: Rxulti ohutusprofiil on sarnane teiste antipsühhootiliste ravimitega.
English: These neurotransmitters play a role in schizophrenia, and by acting at their receptors, brexpiprazole helps normalise the activity of the brain and reduce symptoms of schizophrenia.
Estonian: Nimetatud virgatsained mängivad skisofreenia korral rolli ja nende retseptoritesse toimides aitab brekspiprasool normaliseerida aju tööd ja vähendada skisofreenia sümptomeid.
English: What is Rxulti and what is it used for?
Estonian: Mis on Rxulti ja milleks seda kasutatakse?
English: Other information about Rxulti
Estonian: Muu teave Rxulti kohta
English: In patients with moderately or severely reduced kidney or liver function the dose should be limited to 3 mg once a day.
Estonian: Mõõduka või raske neeru- või maksakahjustusega patsientidel ei tohi annus ületada 3 mg üks kord ööpäevas.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rxulti have been included in the summary of product characteristics and the package leaflet.
Estonian: Rxulti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: For more information about using Rxulti, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Rxulti kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: As for all medicines, data on the use of Rxulti are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Rxulti kasutamise kohta pidevat järelevalvet.
English: Side effects reported with Rxulti are carefully evaluated and any necessary action taken to protect patients.
Estonian: Rxulti kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Rxulti has been shown to be effective at reducing symptoms of schizophrenia in 5 main studies involving 2,404 adults with schizophrenia, although there were some inconsistent results.
Estonian: Rxulti efektiivsus skisofreenia sümptomite vähendamisel on tõestatud 5 põhiuuringus, milles osales 2404 skisofreeniaga täiskasvanud patsienti, kuigi uuringutes saadi ka mõningaid ebajärjepidevaid tulemusi.
English: The fifth study compared Rxulti with placebo over one year, and the main measure of effectiveness was the risk of relapse (worsening of symptoms).
Estonian: Viiendas uuringus võrreldi Rxultit platseeboga ühe aasta jooksul ja efektiivsuse põhinäitaja oli retsidiivi risk (sümptomite süvenemine).
English: Rxulti was more effective than placebo in preventing relapse: after a year, 14% of patients taking Rxulti had relapsed compared with 38% of patients taking placebo.
Estonian: Rxulti oli retsidiivi ennetamisel platseebost efektiivsem: ühe aasta pärast oli Rxulti võtnutest retsidiiv tekkinud 14% patsientidest ja platseebot võtnutest 38% patsientidest.
English: Results at 2, 3 and 4 weeks showed improvement in symptoms with Rxulti compared with placebo.
Estonian: 2., 3. ja 4. nädala tulemused näitasid sümptomite paranemist Rxulti rühmas võrreldes platseeboga.
English: Rxulti is an antipsychotic medicine used to treat schizophrenia in adults.
Estonian: Rxulti on antipsühhootikum, mida kasutatakse skisofreenia raviks täiskasvanutel.
English: Rxulti was effective at reducing symptoms of schizophrenia.
Estonian: Rxulti oli skisofreenia sümptomite vähendamisel efektiivne.
English: The most common side effects with Rxulti are akathisia (a constant urge to move, which may affect around 6 in 100 people) and weight gain (which may affect around 4 in 100 people).
Estonian: Rxulti kõige sagedamad kõrvalnähud on akatiisia (pidev tung liikuda; mis võib esineda ligikaudu 6 patsiendil 100st) ja kaalutõus (mis võib esineda ligikaudu 4 patsiendil 100st).
English: In 4 of the studies, Rxulti was compared with placebo (a dummy treatment) and the main measure of effectiveness was reduction of symptoms on a standard rating scale called PANSS (positive and negative syndrome scale) which ranges from a minimum of 30 (no symptoms) to a maximum of 210 (severest symptoms) after 6 weeks of treatment.
Estonian: 4 uuringus võrreldi Rxulti platseeboga (näiva ravimiga) ja efektiivsuse põhinäitaja oli sümptomite vähenemine 6nädalase ravi järel, hinnatuna standardsel hindamisskaalal PANSS (positiivse ja negatiivse sündroomi skaala), mille tulemus varieerub miinimumtulemusest 30 (sümptomid puuduvad) kuni maksimumtulemuseni 210 (tugevaimad sümptomid).
English: The active substance in Rxulti, brexpiprazole, is thought to attach to receptors (targets) in the brain for several neurotransmitters (substances nerve cells use to communicate with neighbouring cells) including dopamine, serotonin and noradrenaline.
Estonian: Arvatakse, et Rxulti toimeaine brekspiprasool seondub ajus mitme virgatsaine, sealhulgas dopamiini, serotoniini ja noradrenaliini retseptoriga (sihtmärgiga).
English: Rxulti contains the active substance brexpiprazole.
Estonian: Rxulti sisaldab toimeainena brekspiprasooli.
English: The recommended dose is between 2 and 4 mg daily and 4 mg is the maximum recommended daily dose.
Estonian: Soovitatav annus on 2 kuni 4 mg ööpäevas ja 4 mg on maksimaalne soovitatav ööpäevane annus.
English: For the full list of side effects and restrictions with Rxulti, see the package leaflet.
Estonian: Rxulti kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: What are the risks associated with Rxulti?
Estonian: Mis riskid Rxultiga kaasnevad?
English: How is Rxulti used?
Estonian: Kuidas Rxulti kasutatakse?
English: How does Rxulti work?
Estonian: Kuidas Rxulti toimib?
English: After 6 weeks, there was not considered to be a difference between Rxulti and placebo.
Estonian: 6 nädala pärast ei täheldatud Rxulti ja platseebo vahel erinevust.
English: Quetiapine showed improvement in symptoms at 6 weeks compared with placebo.
Estonian: Kvetiapiiniga saadi platseeboga võrreldes sümptomite paranemine 6 nädala järel.
English: The recommended starting dose is 1 mg once daily for the first 4 days.
Estonian: Soovituslik algannus on 1 mg manustatuna üks kord ööpäevas 4 esimese ravipäeva jooksul.
English: Although the reductions in symptoms were not consistent across the studies, this often occurs in studies with antipsychotic medicines and the European Medicines Agency considered that the effects were sufficient to conclude that Rxulti is beneficial to patients with schizophrenia.
Estonian: Kuigi sümptomite vähenemine ei olnud uuringutes järjepidev, saadakse antipsühhootiliste ravimite uuringutes sageli selliseid tulemusi.
English: However, there was not considered to be a difference between 2 mg Rxulti and placebo.
Estonian: 2 mg Rxulti ja platseebo vahel erinevust ei täheldatud.
English: What benefits of Rxulti have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Rxulti kasulikkus?
English: An overview of Rxulti and why it is authorised in the EU
Estonian: Ülevaade ravimist Rxulti ja ELis müügiloa väljastamise põhjendus
English: In the fourth study, doses of Rxulti ranging from 2 to 4 mg were compared with placebo and with another antipsychotic medicine, quetiapine.
Estonian: Neljandas uuringus võrreldi Rxulti annuseid 2 mg kuni 4 mg platseeboga ja veel ühe antipsühhootilise ravimi kvetiapiiniga.
English: In the third study, the PANSS score fell by around 15 points with 2 mg Rxulti compared with 8 points with placebo and there was not considered to be a difference between 4 mg Rxulti and placebo.
Estonian: Kolmandas uuringus vähenes PANSSi tulemus 2 mg Rxulti kasutamisel 15 punkti ja platseebo kasutamisel 8 punkti ning 4 mg Rxulti ja platseebo vahel erinevust ei täheldatud.
English: Rxulti can only be obtained with a prescription.
Estonian: Rxulti on retseptiravim.
English: The dose is then increased to 2 mg once daily taken on days 5, 6 and 7 and increased again if necessary to 4 mg once daily on day 8.
Estonian: Seejärel suurendatakse annust 2 mg-ni üks kord ööpäevas 5., 6. ja 7. ravipäeval.
English: In the first study, the PANSS score fell by around 21 and 20 points with 2 mg and 4 mg Rxulti respectively compared with 12 points with placebo.
Estonian: Esimeses uuringus vähenes PANSSi tulemus 2 mg ja 4 mg Rxulti kasutamisel vastavalt 21 ja 20 punkti võrreldes platseeboga saadud 12punktilise vähenemisega.
English: In the second study, the PANSS score fell by around 20 points with 4 mg Rxulti compared with 14 points with placebo.
Estonian: Teises uuringus vähenes PANSSi tulemus 4 mg Rxulti kasutamisel 20 punkti võrreldes platseeboga saadud 14punktilise vähenemisega.
English: Annex I List of medicinal products and presentations
Estonian: I LISA RIIKLIKULT HEAKSKIIDETUD RAVIMITE LOETELU
English: These reactions should disappear within two to three days.
Estonian: Need reaktsioonid peaksid kaduma kahe kuni kolme päeva jooksul.
English: This helps to reduce the symptoms of babesiosis.
Estonian: See aitab babesioosi sümptomeid vähendada.
English: Only healthy dogs should be vaccinated.
Estonian: Vaktsineerida tohib ainult terveid koeri.
English: In general, these disappear within four days, but in rare cases they can persist for up to 14 days after the second injection.
Estonian: Üldjuhul need kaovad nelja päeva jooksul, kuid vahel harva võivad püsida kuni 14 päeva pärast teist süsti.
English: This summary was last updated on 30 August 2007.
Estonian: Kokkuvõtte viimane uuendus: 30-08-2007.
English: If mild symptoms occur and last for more than two days, veterinary advice should be sought.
Estonian: Kui tekivad kerged sümptomid, mis püsivad kauem kui kaks päeva, tuleb pidada nõu veterinaararstiga.
English: When a dog is given the vaccine, the immune system recognises the antigens as ‘foreign' and makes antibodies against them.
Estonian: Kui koerale antakse vaktsiini, peab immuunsüsteem antigeene "võõrasteks" ja produtseerib nende vastu antikehi.
English: The vaccine also contains an ‘adjuvant' (a compound called saponin) to stimulate a better response.
Estonian: Vaktsiin sisaldab parema ravivastuse stimuleerimiseks ka adjuvanti (ühendit nimetusega saponiin).
English: Immunity starts three weeks after the vaccination course and lasts for at least six months.
Estonian: Immuunsus tekib kolme kuu möödumisel vaktsineerimiskuurist ning püsib vähemalt kuus kuud.
English: It is recommended that the vaccination is given at least one month before the tick season and exposure to ticks be reduced during the vaccination period.
Estonian: Vaktsineerida on soovitatav vähemalt üks kuu enne puugihooaja algust ning vaktsineerimise ajal vähendada puukidega kokkupuutumise võimalusi.
English: If accidental self-injection occurs, seek medical advice immediately and show the Package Leaflet or the label to the doctor.
Estonian: Juhusliku iseenesele süstimise korral pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
English: Nobivac Piro is a vaccine.
Estonian: Nobivac Piro on vaktsiin.
English: Dogs that are infected with B. canis but have no symptoms should be treated appropriately before vaccination.
Estonian: B. canis'ega nakatunud koeri, kellel sümptomid puuduvad, tuleb enne vaktsineerimist nõuetekohaselt ravida.
English: After vaccination, painful swelling or hardened nodules occur commonly at the site of vaccination.
Estonian: Pärast vaktsineerimist tekivad vaktsineerimiskohal sageli valulik turse või kõvad sõlmed.
English: Because the antigens on B. canis are very variable, vaccines against B. canis only work effectively if they also include antigens from B. rossi.
Estonian: Kuna B. canis'e antigeenid on väga varieeruvad, toimivad B. canis'e vaktsiinid efektiivselt vaid sel juhul, kui need sisaldavad ka B. rossi antigeene.
English: Information on the prescription status of this product may be found on the label/outer package.
Estonian: Teave selle kohta, kas toode on retseptiravim, on esitatud sildil/välispakendil.
English: For initial vaccination, Nobivac Piro is given as two 1-ml injections under the skin three to six weeks apart.
Estonian: Baasvaktsineerimiseks manustatakse Nobivac Pirot kahe 1 ml süstina naha alla kolme- kuni kuuenädalase intervalliga.
English: Side effects such as lethargy (listlessness) and a reduction in appetite are also common, sometimes accompanied by fever and a stiff gait.
Estonian: Sagedad kõrvalnähud on ka letargia (loidus) ja isu vähenemine, millega mõnikord kaasnevad palavik ja jäik kõnnak.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nobivac Piro to Intervet International B.V. on 2 September 2004.
Estonian: Euroopa Komisjon väljastas Nobivac Piro müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Intervet International B.V.
English: Further one main field study was performed, including dogs of at least six months of age of various breeds who received two injections of Nobivac Piro three weeks apart.
Estonian: Ühes peamises väliuuringus uuriti ka vähemalt kuue kuu vanuseid erinevat tõugu koeri, kes said kaks Nobivac Piro süsti kolmenädalase intervalliga.
English: The vaccine can reduce the severity of symptoms caused by acute (short-lived) babesiosis (the disease caused by infection with B. canis, with weakness, fever and jaundice) and anaemia (low red blood cell counts).
Estonian: Vaktsiin võib vähendada ägeda (lühiajalise) babesioosi (B. canis'ega nakatumisest põhjustatud haigus, millele on iseloomulik nõrkus, palavik ja kollatõbi) ja aneemia (punaliblede vähesus) sümptomite raskust.